Literature DB >> 27194572

Effects of uric-acid-lowering therapy on renal outcomes: the future looks promising.

Vassilis Filiopoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27194572     DOI： 10.1038/hr.2016.52

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  13 in total

1.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors:  Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

Review 2.  New insights into uric acid effects on the progression and prognosis of chronic kidney disease.

Authors:  Vassilis Filiopoulos; Dimitrios Hadjiyannakos; Dimosthenis Vlassopoulos
Journal:  Ren Fail       Date:  2012-01-20       Impact factor: 2.606

Review 3.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

4.  Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension.

Authors:  Masanari Kuwabara; Koichiro Niwa; Yutaro Nishi; Atsushi Mizuno; Taku Asano; Keita Masuda; Ikki Komatsu; Masahiro Yamazoe; Osamu Takahashi; Ichiro Hisatome
Journal:  Hypertens Res       Date:  2014-03-27       Impact factor: 3.872

5.  Associations between serum uric acid levels and the incidence of hypertension and metabolic syndrome: a 4-year follow-up study of a large screened cohort in Okinawa, Japan.

Authors:  Kazufumi Nagahama; Taku Inoue; Kentaro Kohagura; Kozen Kinjo; Yusuke Ohya
Journal:  Hypertens Res       Date:  2014-11-06       Impact factor: 3.872

6.  Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Dipankar Sircar; Soumya Chatterjee; Rajesh Waikhom; Vishal Golay; Arpita Raychaudhury; Suparna Chatterjee; Rajendra Pandey
Journal:  Am J Kidney Dis       Date:  2015-07-30       Impact factor: 8.860

7.  Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Authors:  Yugo Shibagaki; Iwao Ohno; Tatsuo Hosoya; Kenjiro Kimura
Journal:  Hypertens Res       Date:  2014-06-19       Impact factor: 3.872

8.  Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.

Authors:  Gerald D Levy; Nazia Rashid; Fang Niu; T Craig Cheetham
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

9.  Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.

Authors:  Kentaro Kohagura; Takeshi Tana; Akira Higa; Masanobu Yamazato; Akio Ishida; Kazufumi Nagahama; Atsushi Sakima; Kunitoshi Iseki; Yusuke Ohya
Journal:  Hypertens Res       Date:  2016-04-14       Impact factor: 3.872

Review 10.  Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies.

Authors:  Ling Li; Chen Yang; Yuliang Zhao; Xiaoxi Zeng; Fang Liu; Ping Fu
Journal:  BMC Nephrol       Date:  2014-07-27       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.